Form 4: Pfizer CEO Albert Bourla Increases Phantom Stock Holdings

Pfizer's Chairman and CEO, Albert Bourla, acquired additional phantom stock units through the company's deferred compensation plan, increasing his indirect beneficial ownership.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., acquired additional phantom stock units.
• On July 14, 2025, 80 phantom stock units were acquired at a price of $25.35 per unit.
• On July 15, 2025, an additional 24 phantom stock units were acquired at a price of $24.61 per unit.
• Following these transactions, Bourla's total beneficial ownership of phantom stock units increased to 718,359.
• These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, representing phantom shares of common stock settled in cash upon separation from service.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock units by the CEO is generally a positive signal, indicating alignment of interests and long-term commitment. While not a direct stock purchase, it reflects participation in a compensation plan tied to company performance. The routine nature of the transaction prevents a higher score.

Positives

• Acquisition of phantom stock units by the CEO indicates continued alignment of management's interests with shareholder value.
• Participation in the deferred compensation plan suggests a long-term commitment to the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding Pfizer's future performance or strategic outlook.

Industry Context

This insider transaction, a routine acquisition of phantom stock units through a deferred compensation plan, is common among senior executives in the pharmaceutical industry and does not directly reflect broader industry trends or competitive shifts. It primarily signifies executive participation in long-term incentive programs.

Comparison to Industry Standards

• The acquisition of phantom stock units through a deferred compensation plan is a standard practice for executive compensation across large-cap pharmaceutical companies, including peers like Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV).
• These plans are designed to align executive interests with long-term shareholder value and are not typically indicative of specific company performance relative to competitors, but rather a common component of executive remuneration packages.

Related Party Transactions

• Albert Bourla, Chairman & CEO, acquired phantom stock units from Pfizer Inc. through the company's Nonfunded Deferred Compensation and Supplemental Savings Plan.

Stakeholder Impact

• Shareholders: The increase in phantom stock ownership by the CEO aligns his long-term financial interests with those of shareholders, potentially fostering greater commitment to increasing shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Key Dates

Recommendation

Keywords

Pfizer, PFE, Albert Bourla, SEC Form 4, Insider Trading, Phantom Stock Units, Deferred Compensation, Executive Compensation, Stock Ownership